# Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

> **NCT07413601** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 78 (estimated)

## Conditions studied

- Triple Negative Breast Cancer Metastatic

## Interventions

- **DRUG:** QL1706
- **DRUG:** Cisplatin/ Carboplatin

## Key facts

- **NCT ID:** NCT07413601
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-10
- **Primary completion:** 2029-02-10
- **Final completion:** 2029-02-10
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07413601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07413601, "Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07413601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*